Why I do not treat patients for mild disease

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis C (HCV) with mild disease has a favorable short-term prognosis.
• Non-invasive tests facilitate monitoring of fibrosis progression.
• Current interferon (IFN)- and ribavirin (RBV)-free regimens achieve high sustained viral response (SVR) rates.

Purpose of the Study:

• To evaluate the efficacy and safety of current direct-acting antiviral (DAA) regimens for mild chronic hepatitis C.
• To assess the potential for shorter treatment durations (8 weeks) in this patient population.
• To analyze the cost-effectiveness and practical implications of current HCV treatment strategies.

Main Methods:

• Review of clinical trial data and real-life experience with all-oral DAA regimens.
• Analysis of sustained viral response (SVR) rates, treatment duration, and safety profiles.
• Assessment of non-invasive fibrosis markers and cost-effectiveness.

Main Results:

• Current DAA regimens provide SVR rates exceeding 90% with 12-week treatment for most mild HCV patients.
• An 8-week treatment duration may be feasible for mild disease, pending further data.
• Current regimens are not cost-effective for patients with mild HCV.

Conclusions:

• Deferring treatment and monitoring fibrosis progression is a safe strategy for mild HCV until more cost-effective and convenient options are available.
• Further clinical trials and real-world data are necessary to confirm the utility of 8-week treatment durations.
• Optimizing DAA combinations can improve efficacy and safety outcomes for chronic hepatitis C management.